New hope for brain tumor patients: drug trial targets recurrent meningioma

NCT ID NCT05425004

Recruiting now Disease control Sponsor: Baptist Health South Florida Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the drug cabozantinib in 24 people with meningioma that has come back or worsened after standard treatments like surgery or radiation. The main goal is to see if the drug can stop the tumor from growing for at least 6 months. Participants must have a Karnofsky score of 50 or higher and adequate blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system cancer meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENINGIOMA

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 100653, United States
Miami Cancer Institute at Baptist Health, Inc.
RECRUITING

Miami, Florida, 33176, United States
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.